GT Biopharma Inc (GTBP) - Total Assets
Based on the latest financial reports, GT Biopharma Inc (GTBP) holds total assets worth $10.00 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GT Biopharma Inc - Total Assets Trend (1983–2025)
This chart illustrates how GT Biopharma Inc's total assets have evolved over time, based on quarterly financial data. Also see GT Biopharma Inc stock valuation for the company's overall valuation and market capitalisation.
GT Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
GT Biopharma Inc's total assets of $10.00 Million consist of 100.0% current assets and 0.0% non-current assets. Review GT Biopharma Inc (GTBP) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1983–2025)
This chart illustrates how GT Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of GT Biopharma Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GT Biopharma Inc's current assets represent 100.0% of total assets in 2025, an increase from 88.6% in 1983.
- Cash Position: Cash and equivalents constituted 84.0% of total assets in 2025, up from 57.1% in 1983.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1983.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GT Biopharma Inc Competitors by Total Assets
Key competitors of GT Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
GT Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.69 | 0.73 | 12.08 |
| Quick Ratio | 3.69 | 0.73 | 12.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.51 Million | $-980.00K | $36.29 Million |
GT Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between GT Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.52 |
| Latest Market Cap to Assets Ratio | 1.43 |
| Asset Growth Rate (YoY) | 91.5% |
| Total Assets | $8.11 Million |
| Market Capitalization | $11.56 Million USD |
Valuation Analysis
Above Book Valuation: The market values GT Biopharma Inc's assets above their book value (1.43x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: GT Biopharma Inc's assets grew by 91.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GT Biopharma Inc (1983–2025)
The table below shows the annual total assets of GT Biopharma Inc from 1983 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.11 Million | +91.54% |
| 2024-12-31 | $4.23 Million | -70.00% |
| 2023-12-31 | $14.11 Million | -15.70% |
| 2022-12-31 | $16.74 Million | -47.97% |
| 2021-12-31 | $32.17 Million | +468.26% |
| 2020-12-31 | $5.66 Million | +1329.55% |
| 2019-12-31 | $396.00K | -98.44% |
| 2018-12-31 | $25.40 Million | -90.01% |
| 2017-12-31 | $254.37 Million | +1017372.00% |
| 2016-12-31 | $25.00K | -53.70% |
| 2015-12-31 | $54.00K | -93.92% |
| 2014-12-31 | $888.00K | +504.08% |
| 2013-12-31 | $147.00K | -34.96% |
| 2012-12-31 | $226.00K | +75.19% |
| 2011-12-31 | $129.00K | -30.27% |
| 2010-12-31 | $185.00K | -86.63% |
| 2009-12-31 | $1.38 Million | +134.58% |
| 2008-12-31 | $590.00K | -87.85% |
| 2007-12-31 | $4.86 Million | -39.26% |
| 2006-12-31 | $8.00 Million | +2.45% |
| 2005-12-31 | $7.81 Million | -7.90% |
| 2004-12-31 | $8.48 Million | +331.79% |
| 2003-12-31 | $1.96 Million | -1.11% |
| 2002-12-31 | $1.99 Million | +15.34% |
| 2001-12-31 | $1.72 Million | -69.40% |
| 2000-12-31 | $5.62 Million | +8.51% |
| 1999-12-31 | $5.18 Million | -53.71% |
| 1998-12-31 | $11.20 Million | -11.11% |
| 1997-12-31 | $12.60 Million | +57.50% |
| 1996-12-31 | $8.00 Million | -19.19% |
| 1995-12-31 | $9.90 Million | -11.61% |
| 1994-12-31 | $11.20 Million | +261.29% |
| 1993-12-31 | $3.10 Million | -36.73% |
| 1992-12-31 | $4.90 Million | +2.08% |
| 1991-12-31 | $4.80 Million | -4.00% |
| 1990-12-31 | $5.00 Million | +13.64% |
| 1989-12-31 | $4.40 Million | +25.71% |
| 1988-12-31 | $3.50 Million | +6.06% |
| 1987-12-31 | $3.30 Million | 0.00% |
| 1986-12-31 | $3.30 Million | +3.13% |
| 1985-12-31 | $3.20 Million | -15.79% |
| 1984-12-31 | $3.80 Million | +8.57% |
| 1983-12-31 | $3.50 Million | -- |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more